Want to see ONCY full AI Analyst Report?
Oncolytics Biotech (ONCY) Stock Statistics & Valuation Metrics
Total Valuation
Oncolytics Biotech has a market cap or net worth of $51.00M. The enterprise value is $110.07M.
- Market Cap
- $51.00M
- Enterprise Value
- $110.07M
Share Statistics
Oncolytics Biotech has 127,510,506 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 127,510,506
- Owned by Insiders
- 1.68%
- Owned by Institutions
- 0.74%
Financial Efficiency
Oncolytics Biotech’s return on equity (ROE) is 5.52 and return on invested capital (ROIC) is -1250.57%.
- Return on Equity (ROE)
- 5.52
- Return on Assets (ROA)
- -2.76
- Return on Invested Capital (ROIC)
- -1250.57%
- Return on Capital Employed (ROCE)
- -14.14
- Revenue Per Employee
- 0
- Profits Per Employee
- -991.69K
- Employee Count
- 29
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Oncolytics Biotech is -1.58. Oncolytics Biotech’s PEG ratio is 0.06.
- PE Ratio
- -1.58
- PS Ratio
- 0.00
- PB Ratio
- -10.58
- Price to FCF
- -1.89
- Price to Operating Cash Flow
- -2.26
- PEG Ratio
- 0.06
Income Statement
In the last 12 months, Oncolytics Biotech had revenue of 0 and earned -28.76M in profits. Earnings per share was -0.41.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -28.73M
- Pretax Income
- -28.68M
- Net Income
- -28.76M
- EBITDA
- -28.66M
- Earnings Per Share (EPS)
- -0.41
Cash Flow
In the last 12 months, operating cash flow was -28.92M and capital expenditures -12,598, giving a free cash flow of -28.93M billion.
- Operating Cash Flow
- -28.92M
- Free Cash Flow
- -28.93M
- Free Cash Flow per Share
- -0.24
Dividends & Yields
Oncolytics Biotech pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -53.50%
- Earnings Yield
- -59.21%
Stock Price Statistics
- Beta
- 1.43
- 52-Week Price Change
- -64.22%
- 50-Day Moving Average
- 0.67
- 200-Day Moving Average
- 0.86
- Relative Strength Index (RSI)
- 20.65
- Average Volume (3m)
- 1.04M
Important Dates
Oncolytics Biotech upcoming earnings date is Feb 26, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 30, 2026
- Next Earnings Date
- Feb 26, 2027
- Ex-Dividend Date
- ―
Financial Position
Oncolytics Biotech as a current ratio of 1.12, with Debt / Equity ratio of -14.82%
- Current Ratio
- 1.12
- Quick Ratio
- 1.12
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.22
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Oncolytics Biotech has paid 79.00K in taxes.
- Income Tax
- 79.00K
- Effective Tax Rate
- -0.00
Enterprise Valuation
Oncolytics Biotech EV to EBITDA ratio is -1.33, with an EV/FCF ratio of -1.74.
- EV to Sales
- 0.00
- EV to EBITDA
- -1.33
- EV to Free Cash Flow
- -1.74
- EV to Operating Cash Flow
- -1.74
Balance Sheet
Oncolytics Biotech has $4.12M in cash and marketable securities with $448.00K in debt, giving a net cash position of $3.67M billion.
- Cash & Marketable Securities
- $4.12M
- Total Debt
- $448.00K
- Net Cash
- $3.67M
- Net Cash Per Share
- $0.03
- Tangible Book Value Per Share
- -$0.05
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Oncolytics Biotech is $5.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $5.00
- Price Target Upside
- 1182.05% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 3
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 2.05%
Scores
- Smart Score
- 5
- AI Score
- 45
